315 related articles for article (PubMed ID: 25115989)
1. Treatment of bone metastases in urologic malignancies.
Froehner M; Hölscher T; Hakenberg OW; Wirth MP
Urol Int; 2014; 93(3):249-56. PubMed ID: 25115989
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
3. Management of bone metastases in patients with castration-resistant prostate cancer.
Cathomas R; Bajory Z; Bouzid M; El Ghoneimy A; Gillessen S; Goncalves F; Kacso G; Kramer G; Milecki P; Pacik D; Tantawy W; Lesniewski-Kmak K
Urol Int; 2014; 92(4):377-86. PubMed ID: 24802278
[TBL] [Abstract][Full Text] [Related]
4. Progress in the treatment of bone metastases in cancer patients.
Mackiewicz-Wysocka M; Pankowska M; Wysocki PJ
Expert Opin Investig Drugs; 2012 Jun; 21(6):785-95. PubMed ID: 22500564
[TBL] [Abstract][Full Text] [Related]
5. New and emerging therapies for bone metastases in genitourinary cancers.
Saylor PJ; Armstrong AJ; Fizazi K; Freedland S; Saad F; Smith MR; Tombal B; Pienta K
Eur Urol; 2013 Feb; 63(2):309-20. PubMed ID: 23201471
[TBL] [Abstract][Full Text] [Related]
6. [Management of bone metastases].
Nagykálnai T; Landherr L
Orv Hetil; 2014 Feb; 155(6):217-25. PubMed ID: 24486845
[TBL] [Abstract][Full Text] [Related]
7. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.
Carter JA; Botteman MF
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):425-37. PubMed ID: 22540167
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
Saad F; Eastham JA
Semin Oncol; 2010 Jun; 37 Suppl 1():S38-44. PubMed ID: 20682371
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
Coleman RE
Curr Opin Support Palliat Care; 2012 Sep; 6(3):322-9. PubMed ID: 22801464
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
12. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates: prevention of bone metastases in prostate cancer.
Saad F; Lattouf JB
Recent Results Cancer Res; 2012; 192():109-26. PubMed ID: 22307372
[TBL] [Abstract][Full Text] [Related]
14. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Lipton A; Colombo-Berra A; Bukowski RM; Rosen L; Zheng M; Urbanowitz G
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
[TBL] [Abstract][Full Text] [Related]
15. Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid.
Cappetta A; Spano L; Evangelista L; Zovato S; Opocher G; Pastorelli D
Anticancer Drugs; 2015 Feb; 26(2):232-5. PubMed ID: 25243456
[TBL] [Abstract][Full Text] [Related]
16. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
[TBL] [Abstract][Full Text] [Related]
17. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
[TBL] [Abstract][Full Text] [Related]
18. Effects of bone-targeted agents on cancer progression and mortality.
Coleman R; Gnant M; Morgan G; Clezardin P
J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
[TBL] [Abstract][Full Text] [Related]
19. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
20. Skeletal Health Part 2: Development of a Nurse Practitioner Bone Support Clinic for Urologic Patients.
Turner B; Ali S; Drudge-Coates L; Pati J; Nargund V; Wells P
Urol Nurs; 2016; 36(1):22-6. PubMed ID: 27093760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
